- Home
- LCTX vs EML Comparison
LCTX vs EML Comparison
Compare LCTX & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- EML
- Stock Information
- Founded
- LCTX 1990
- EML 1858
- Country
- LCTX United States
- EML United States
- Employees
- LCTX N/A
- EML N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- EML Industrial Machinery/Components
- Sector
- LCTX Health Care
- EML Consumer Discretionary
- Exchange
- LCTX Nasdaq
- EML Nasdaq
- Market Cap
- LCTX 165.6M
- EML 171.1M
- IPO Year
- LCTX N/A
- EML N/A
- Fundamental
- Price
- LCTX $0.88
- EML $30.66
- Analyst Decision
- LCTX Strong Buy
- EML
- Analyst Count
- LCTX 3
- EML 0
- Target Price
- LCTX $5.67
- EML N/A
- AVG Volume (30 Days)
- LCTX 307.7K
- EML 30.4K
- Earning Date
- LCTX 11-07-2024
- EML 11-05-2024
- Dividend Yield
- LCTX N/A
- EML 1.44%
- EPS Growth
- LCTX N/A
- EML 65.47
- EPS
- LCTX N/A
- EML 1.92
- Revenue
- LCTX $6,186,000.00
- EML $273,702,675.00
- Revenue This Year
- LCTX N/A
- EML N/A
- Revenue Next Year
- LCTX $119.00
- EML N/A
- P/E Ratio
- LCTX N/A
- EML $16.43
- Revenue Growth
- LCTX N/A
- EML N/A
- 52 Week Low
- LCTX $0.77
- EML $16.10
- 52 Week High
- LCTX $1.61
- EML $35.78
- Technical
- Relative Strength Index (RSI)
- LCTX 53.88
- EML 52.76
- Support Level
- LCTX $0.83
- EML $28.68
- Resistance Level
- LCTX $0.94
- EML $31.99
- Average True Range (ATR)
- LCTX 0.05
- EML 0.89
- MACD
- LCTX 0.01
- EML -0.00
- Stochastic Oscillator
- LCTX 89.45
- EML 46.22
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.